Business Wire

New Peer Reviewed Research Reinforces the Carbon Neutrality of Sustainably Sourced Biomass in the U.S. Southeast

8.2.2023 15:00:00 EET | Business Wire | Press release

Share

Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced woody biomass, along with the U.S. Industrial Pellet Association (USIPA), welcome a recent study, titled “Impacts of the US southeast wood pellet industry on local forest carbon stocks.” The study has been peer-reviewed and published in a leading scientific journal, Nature, confirming that the wood pellet industry has met the overall condition of forest carbon neutrality in the U.S. Southeast between 2000 and 2019.

According to the International Energy Agency (IEA), if harvest volumes (for wood products and energy) and losses related to mortality and disturbances do not exceed the growth across the whole forest, there is no net reduction in forest carbon stock. The 2022 study in Nature additionally confirms, by data, that carbon neutrality guidelines have been met by biomass producers in the U.S. Southeast, which is the world’s leading region for wood pellet production and export. Between 2000 and 2019, data and observations were collected from more than 19,000 forest inventory tracts maintained by the U.S. Forest Service. At the completion of the study, researchers concluded that, “our estimates offer robust evidence that the wood pellet industry has met the overall condition of forest carbon neutrality.”

In parallel to the IEA, The United Nations Intergovernmental Panel on Climate Change’s “Special Report on Climate Change and Land” stated, “In the long term, a sustainable forest management strategy aimed at maintaining or increasing forest carbon stocks, while producing an annual sustained yield of timber, fiber, or energy from the forest, will generate the largest sustained mitigation benefit” (Ch 4, 4.8.5, page 66).

“These studies build on the scientific literature that consistently shows existing regulations are working as intended to ensure biomass is responsibly sourced in the U.S. Southeast to provide a positive impact on the climate and the environment,” said Amandine Muskus, Executive Director at USIPA. “Woody biomass critics often argue that wood pellet production in the U.S. Southeast reduces carbon stocks and creates a carbon debt that accelerates climate change. However, there is no published research that has been subjected to the rigors of independent peer review that supports these claims. Indeed, they are directly refuted by the weight of empirical scientific evidence.”

The aforementioned study corroborates a growing body of scholarly research on the topic that has been subjected to peer review and published in leading academic journals. For example, published in 2017, in Forest Ecology and Management, was a study titled “How is wood-based pellet production affecting forest conditions in the southeastern United States?” That study concluded “benefits accrue when sustainable forest management provides wood pellets for energy that keep fossil fuel in the ground.” Likewise, another study was published in Nature in 2020, titled “Expansion of US wood pellet industry points to positive trends but the need for continued monitoring.” This study found that wood pellet production in the U.S. “is compliant with current European Union Renewable Energy Directive (RED) biofuel trade requirements for the preservation of carbon stocks in biomass sourcing areas.”

“Enviva remains committed to sourcing wood pursuant to our strict, global Responsible Sourcing Policy and in line with the principles set out in the Glasgow Declaration on Sustainable Bioenergy launched at COP 26,” said Enviva’s Chief Sustainability Officer, Brandi Colander. “Enviva augments the productivity of these working forests by expanding the wood products market for the parts of the harvested wood that are not fully utilized in other higher-value markets. Markets drive demand. The stronger the demand is for forest products, the more forests grow, and that is because private landowners continue to invest in forests where there are markets for forest products.”

In addition to peer-reviewed studies, third-party data, such as the U.S. Forest Service’s Forest Inventory and Analysis (FIA) Program, shows that increased demand for forest products in the U.S. Southeast has resulted in more, not less, forest inventory in the region year over year. In fact, since 1953, FIA data indicates that forest inventories in the U.S. Southeast have more than doubled while the region has continued to be an important wood basket.

Further corroborating the scientific arguments from the three peer-reviewed papers, the Biden administration recently reaffirmed the carbon neutrality of forest bioenergy in the $1.7 trillion omnibus spending bill, provided the use of forest biomass for energy production does not cause conversion of forests to non-forest use. This significant declaration provides additional avenues for the use of sustainability sourced woody biomass in the U.S.’s renewable energy plans, particularly valuable for hard-to-abate heavy industries like lime, steel, and aviation.

To learn more about the carbon benefits of biomass from sustainably sourced forests, we invite you to visit Enviva’s white paper, Biomass: Unlocking a Future Beyond Fossil Fuel.

About Enviva

Enviva Inc. (NYSE: EVA) is the world’s largest producer of industrial wood pellets, a renewable and sustainable energy source produced by aggregating a natural resource, wood fiber, and processing it into a transportable form, wood pellets. Enviva owns and operates ten plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi, and is constructing its 11th plant in Epes, Alabama. Enviva is planning to commence construction of its 12th plant, near Bond, Mississippi, in 2023. Enviva sells most of its wood pellets through long-term, take-or-pay off-take contracts with primarily creditworthy customers in the United Kingdom, the European Union, and Japan, helping to accelerate the energy transition and to decarbonize hard-to-abate sectors like steel, cement, lime, chemicals, and aviation fuels. Enviva exports its wood pellets to global markets through its deep-water marine terminals at the Port of Chesapeake, Virginia, the Port of Wilmington, North Carolina, and the Port of Pascagoula, Mississippi, and from third-party deep-water marine terminals in Savannah, Georgia, Mobile, Alabama, and Panama City, Florida.

To learn more about Enviva, please visit our website at www.envivabiomass.com. Follow Enviva on social media @Enviva.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jacob Westfall
+1-301-657-5560
media@envivabiomass.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye